[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)]
- PMID: 9201724
[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)]
Abstract
Tandospirone (sedil) is a newly developed anxiolytic drug that has a much higher selective affinity for 5-HT1A than dopamine D2 receptors without the binding affinities with noradrenergic, dopaminergic, cholinergic and GABAergic receptors. This agent binds with 5-HT1A receptors located in both 5-HT neurons in the raphe nucleus and other postsynaptic neurons to induce hyperpolarization of the neurons by opening the K+ channels to eventually inhibit the target neuronal activities. With repeated administrations of tandospirone, a decrease in 5-HT2A receptor population was observed. Behavioral studies in experimental animals have demonstrated that tandospirone inhibits conflict in Vogel methods, aggressive behavior and muricide in manners similar to those of diazepam. In addition, tandospirone showed antistress effects in experimental models and antidepressive effects in forced swimming tests. Unlike diazepam, tandospirone does not produce sedative, sleep-inducing, anticonvulsant, nor muscle relaxant effects at doses effective for conflict tests. Drug dependance, one of the serious problems with bezodiazepine, is not observed with repeated treatment of tandospirone in rats and monkeys. Furthermore, tandospirone has been reported to show a significantly more superior or equipotent effect to diazepam in controlling autonomic disturbances, psychiatric cardiovascular and vegetative syndromes as well as neurosis in double blind clinical studies. These effects are probably due to the selective action of tandospirone on 5-HT1A receptors in the limbic system to eventuate anxiolytic and antidepressant effects. A decrease in 5-HT2A receptor population with repeated treatment of tandospirone may have contributed to the antidepressive effect. Furthermore, 5-HT1A receptors relatively, selectively distributed in the limbic system are not involved in sedation, sleep or muscle relaxation. Such unwanted effects of benzodiazepines are thus not observed with tandospirone treatment.
Similar articles
-
Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test.Jpn J Pharmacol. 1992 May;59(1):105-12. doi: 10.1254/jjp.59.105. Jpn J Pharmacol. 1992. PMID: 1354771
-
Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.Brain Res. 2006 Sep 27;1112(1):126-33. doi: 10.1016/j.brainres.2006.07.003. Epub 2006 Aug 1. Brain Res. 2006. PMID: 16884702
-
Tandospirone-induced K+ current in acutely dissociated rat dorsal raphe neurones.Br J Pharmacol. 1998 Jul;124(5):897-904. doi: 10.1038/sj.bjp.0701922. Br J Pharmacol. 1998. PMID: 9692774 Free PMC article.
-
5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.Eur J Pharmacol. 2005 Dec 5;526(1-3):125-39. doi: 10.1016/j.ejphar.2005.09.065. Epub 2005 Nov 28. Eur J Pharmacol. 2005. PMID: 16310183 Review.
-
Behavioral studies of serotonin receptor agonists as antidepressant drugs.J Clin Psychiatry. 1991 Dec;52 Suppl:24-31. J Clin Psychiatry. 1991. PMID: 1684363 Review.
Cited by
-
Effects of selective 5-HT1A agonist tandospirone on the rate and rhythmicity of binocular rivalry.Psychopharmacology (Berl). 2008 Jun;198(2):279-86. doi: 10.1007/s00213-008-1139-2. Epub 2008 Apr 12. Psychopharmacology (Berl). 2008. PMID: 18408919 Clinical Trial.
-
Hematochezia caused by tandospirone in a patient with major depressive disorder and anxious distress: a case report.Front Psychiatry. 2023 Jul 17;14:1209354. doi: 10.3389/fpsyt.2023.1209354. eCollection 2023. Front Psychiatry. 2023. PMID: 37529069 Free PMC article.
-
Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep;32(3):131-7. doi: 10.1007/BF03190475. Eur J Drug Metab Pharmacokinet. 2007. Retraction in: Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):853. doi: 10.1007/s13318-019-00585-5. PMID: 18062405 Retracted.
-
Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.Eur J Drug Metab Pharmacokinet. 2007 Oct-Dec;32(4):233-40. doi: 10.1007/BF03191009. Eur J Drug Metab Pharmacokinet. 2007. PMID: 18348473